ALBANY, N.Y., Dec. 11, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of John Soto as Chief Commercial Officer, a newly created position overseeing the Company's global sales and marketing initiatives.

Mr. Soto joined AngioDynamics in September 2012 as Senior Vice President of the Company's Global Peripheral Vascular Franchise. In addition to his new responsibilities, he will also serve as interim leader of the Peripheral Vascular Franchise as the Company commences a search to fill the position. Additionally, Stephen McGill, Senior Vice President and General Manager, International, will be leaving the Company.

"John Soto has had a tremendous impact on AngioDynamics, driving renewed strength in our Peripheral Vascular Franchise by successfully integrating the AngioVac cannula and circuit into our portfolio, stabilizing the fluid management business and driving growth in the laser segment," said Joseph DeVivo, President and Chief Executive Officer. "While our International business has been a good growth driver for the business, it currently accounts for less than 20% of the Company's global sales. By leveraging John's expansive background in sales and marketing, I believe we can accelerate our international performance.

"John's experience spans from sales and marketing to international markets and regulatory environments, presenting us with a well-rounded leader to hone our global commercial organization. I believe our new structure will build upon our progress by uniting our worldwide sales and marketing resources as we approach the global marketplace," DeVivo continued. "I would also like to thank Stephen McGill for his service. During his tenure Stephen established our international presence, including building a strong team and overseeing the transition to a direct presence in several markets, positioning us well to take these next steps."

Additionally, AngioDynamics announced its Latin American and Canadian teams will be combined with the U.S. sales and marketing teams under the new structure.

Previous to joining AngioDynamics, Mr. Soto was Senior Vice President of Smith & Nephew's Global Hip Franchise. Prior to that, he served as AngioDynamics' Senior Vice President of Global Sales following the Company's acquisition of RITA Medical Systems in 2007, where he had served as Executive Vice President of Global Sales and Vice President of International Operations. Mr. Soto gained leadership experience at Computer Motion, Tyco Healthcare and U.S. Surgical. He graduated from the British Royal Navy with a degree in electronic engineering and has a diploma in medical marketing from the University of California at Los Angeles, Calif.

About AngioDynamics

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.

Trademarks

AngioDynamics, the AngioDynamics logo and AngioVac are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, including Navilyst Medical and its products, R&D capabilities, infrastructure and employees as well as the risk factors listed from time to time in AngioDynamics'SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2013. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

CONTACT: Company Contact:

         AngioDynamics, Inc.Mark Frost, CFO

         (800) 772-6446 x1981

         mfrost@AngioDynamics.com



         Investor Relations Contacts:

         EVC Group, Inc.Michael Polyviou/Robert Jones

         (212) 850-6020; (646) 201-5447

         mpolyviou@evcgroup.com; bjones@evcgroup.com



         Media Contact:

         EVC Group, Inc.John Carter

         (212) 850-6021

         jcarter@evcgroup.com

News Provided by Acquire Media